Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations (Q35692141)

9 August 2017

Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations (English)

1 reference

9 August 2017

1 reference

Natalia Zisman

1

1 reference

9 August 2017

Nancy Dos Santos

2

1 reference

9 August 2017

Sharon Johnstone

3

1 reference

9 August 2017

Alan Tsang

4

1 reference

9 August 2017

David Bermudes

5

1 reference

9 August 2017

Lawrence Mayer

6

1 reference

9 August 2017

Paul Tardi

7

1 reference

9 August 2017

24 January 2011

1 reference

Chemotherapy Research and Practice

9 August 2017

1 reference

9 August 2017

2011

1 reference

9 August 2017

213848

1 reference

Creative Commons Attribution 3.0 Unported

9 August 2017

start time

24 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Ototoxicity from cisplatin therapy in childhood cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265247

25 September 2018

Cisplatin nephrotoxicity

1 reference

12 December 2020

Toxicities in rats with free versus liposomal encapsulated cisplatin

1 reference

12 December 2020

Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution

1 reference

12 December 2020

Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin

1 reference

12 December 2020

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo

1 reference

12 December 2020

Nephrotoxicity of cis-dichlorodiammineplatinum(II)

1 reference

12 December 2020

STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial

1 reference

12 December 2020

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/213848

1 reference

release_zsu64qpmbjggljhujsbvdq2f3i

9 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zsu64qpmbjggljhujsbvdq2f3i

24 November 2022

mapped directly with Wikidata item

PMCID

3265247

1 reference

9 August 2017

1 reference